PRNewsWire
13 Jun 2026, 02:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to inflate revenue. — Allegations of revenue manipulation through channel stuffing are severe and typically lead to significant loss of investor trust and stock price depreciation.
-0.80The lawsuit alleges that ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Deficiencies in internal controls and undisclosed related party transactions suggest governance failures and increase the risk of financial restatements.
-0.60Investors who acquired ADMA securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to file lead plaintiff applications. — The progression of the legal timeline ensures the lawsuit remains active, maintaining a cloud of legal uncertainty over the company.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities class action lawsuit alleging channel stuffing, lack of internal controls, and misleading statements.
The company is mentioned as the subject of a shareholder alert regarding a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
8h ago
